1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D7913C00046, NCT00536107
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 97-02-12, NCT00686322
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: XYL014, NCT00708812
|
|
4.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: simcere002, simcere0802, NCT00813332
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MC#08-002, IIT 12230, NCT00883675
|
|
6.
|
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18
Sponsor: Other
Protocol IDs: P080204, IDRCB 2008-A01386-49, NCT00925444
|
|
7.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MO18109, NCT00949910
|
|
8.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 001-0015-211, NCT00127387
|
|
9.
|
Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 20050113, NCT00243685
|
|
10.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 79
Sponsor: Pharmaceutical / Industry
Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
11.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CT 07-03, NCT00516685
|
|
12.
|
Phase: Phase III, Phase II
Type: Supportive care, Treatment
Status: Active
Age: 17 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: PH-CP010, NCT00518869
|
|
13.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: IFCT-0801, Eudract : 2008-004939-38, NCT00775385
|
|
14.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: SWS-SAKK-16/00, EU-20138, NCT00030771
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CP02-0452, NCT00095199
|
|
16.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRUK-BTOG2-LU3005, EU-20510, NCT00112710
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 20 to 75
Sponsor: Other
Protocol IDs: WJTOG0101, NCT00139971
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 71 and over
Sponsor: Other
Protocol IDs: JCOG0301, C000000059, NCT00132665
|
|
19.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CZOL446G2419, NCT00172042
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 65 and over
Sponsor: Other
Protocol IDs: INJE05-06, NCT00265694
|
|
21.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Surgery in NSCLC stage IIIA/N2, NCT00273494
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRUK-SOCCAR, ISRCTN13746987, EU-20602, EUDRACT-2004-001920-19, NCT00309972
|
|
23.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 75 to 90
Sponsor: Other
Protocol IDs: IFCT-0501, NCT00298415
|
|
24.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2005.386, NCT00300586
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1505, E1505, SWOG-E1505, CALGB-E1505, CAN-NCIC-E1505, NCCTG-E1505, NCT00324805
|
